[Form 4] abrdn Life Sciences Investors Insider Trading Activity

Rhea-AI Filing Summary

abrdn Life Sciences Investors (HQL) insiders Saba Capital Management, L.P. and Boaz Weinstein reported a sale of common stock on 08/21/2025. The filing shows a disposition of 10,710 shares at a price of $14.07 per share. After the reported transaction, the reporting persons beneficially own 3,006,829 shares indirectly. The Form 4 is signed and dated 08/25/2025 and was filed as a joint report by more than one reporting person. No derivative transactions were reported in this filing.

Positive

• Continued substantial indirect ownership: Reporting persons retain 3,006,829 shares following the transaction
• Complete disclosure: Form 4 includes transaction date, price, amount, and signed certification

Negative

• Disposition reported: A sale of 10,710 shares occurred on 08/21/2025 at $14.07 per share

Insights

Securities Analyst

TL;DR: Reporting persons sold a small block while retaining a large indirect stake; transaction appears routine.

The Form 4 records a single non-derivative disposition of 10,710 common shares at $14.07, reducing holdings but leaving an indirect beneficial ownership of 3,006,829 shares. The filing is a joint report by Saba Capital Management, L.P. and Boaz Weinstein and contains no derivative activity. Based solely on the disclosed data, this is a straightforward insider sale with no additional context on purpose or planned future transactions.

Corporate Governance Expert

TL;DR: Insider sale disclosed; significant indirect ownership remains, and disclosure appears complete for the reported transaction.

The report identifies the reporting persons as a director and 10% owner and documents the sale amount, price, and resulting indirect ownership. The form is signed and dated and shows no amendments or derivative instruments. From a governance and disclosure standpoint, the filing satisfies Form 4 reporting requirements for the specific transaction described.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saba Capital Management, L.P.

(Last) (First) (Middle)

405 LEXINGTON AVENUE

58TH FLOOR

(Street)

NEW YORK NY 10174

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
abrdn Life Sciences Investors [ HQL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2025		S		10,710	D	$14.07	3,006,829	I	-

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Saba Capital Management, L.P.

(Last) (First) (Middle)

405 LEXINGTON AVENUE

58TH FLOOR

(Street)

NEW YORK NY 10174

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Weinstein Boaz

(Last) (First) (Middle)

405 LEXINGTON AVENUE

58TH FLOOR

(Street)

NEW YORK NY 10174

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

	Saba Capital Management, L.P. By: Zachary Gindes	08/25/2025
	Boaz Weinstein	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did the insiders of HQL report on the Form 4?

The Form 4 reports a sale of 10,710 common shares on 08/21/2025 at $14.07 per share.

How many HQL shares do the reporting persons own after the transaction?

After the reported sale, the reporting persons beneficially own 3,006,829 shares indirectly.

Who filed the Form 4 for HQL?

The Form 4 was filed by Saba Capital Management, L.P. and Boaz Weinstein as reporting persons; the report is a joint filing.

Did the filing report any derivatives or option exercises for HQL?

No. The filing shows no derivative securities or option transactions; only a non-derivative sale is reported.

When was the Form 4 signed and filed?

The signatures on the filing are dated 08/25/2025.